KRS Capital Management LLC Has $236,000 Stake in Edwards Lifesciences Co. (NYSE:EW)

KRS Capital Management LLC lowered its stake in Edwards Lifesciences Co. (NYSE:EW) by 13.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,100 shares of the medical research company’s stock after selling 480 shares during the period. KRS Capital Management LLC’s holdings in Edwards Lifesciences were worth $236,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Nordea Investment Management AB increased its holdings in shares of Edwards Lifesciences by 1,224.1% in the fourth quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock valued at $123,261,000 after purchasing an additional 1,488,791 shares in the last quarter. Versor Investments LP increased its holdings in shares of Edwards Lifesciences by 83.3% in the third quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock valued at $311,000 after purchasing an additional 2,043 shares in the last quarter. Gateway Investment Advisers LLC increased its holdings in shares of Edwards Lifesciences by 12.2% in the fourth quarter. Gateway Investment Advisers LLC now owns 253,337 shares of the medical research company’s stock valued at $19,317,000 after purchasing an additional 27,519 shares in the last quarter. US Bancorp DE increased its holdings in shares of Edwards Lifesciences by 0.6% in the third quarter. US Bancorp DE now owns 850,257 shares of the medical research company’s stock valued at $58,906,000 after purchasing an additional 5,409 shares in the last quarter. Finally, West Coast Financial LLC increased its holdings in shares of Edwards Lifesciences by 11.7% in the fourth quarter. West Coast Financial LLC now owns 143,644 shares of the medical research company’s stock valued at $10,953,000 after purchasing an additional 15,018 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

EW has been the topic of a number of recent research reports. Stifel Nicolaus raised their price objective on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a research note on Wednesday, February 7th. Morgan Stanley raised their price objective on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research note on Thursday, March 21st. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. Mizuho raised their price objective on shares of Edwards Lifesciences from $85.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, February 7th. Finally, Evercore ISI raised their price objective on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the company an “in-line” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $90.67.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 27,000 shares of Edwards Lifesciences stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the sale, the vice president now directly owns 34,814 shares in the company, valued at approximately $2,980,774.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the transaction, the vice president now directly owns 34,814 shares in the company, valued at approximately $2,980,774.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael A. Mussallem sold 29,350 shares of the business’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $72.98, for a total transaction of $2,141,963.00. Following the transaction, the director now owns 4,486 shares in the company, valued at $327,388.28. The disclosure for this sale can be found here. In the last three months, insiders have sold 218,954 shares of company stock worth $18,735,509. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 1.9 %

EW traded down $1.80 during trading on Thursday, hitting $91.22. The company had a trading volume of 3,929,048 shares, compared to its average volume of 4,032,000. The company has a market capitalization of $54.91 billion, a PE ratio of 40.46, a PEG ratio of 4.67 and a beta of 1.05. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The firm’s 50-day moving average price is $87.93 and its 200 day moving average price is $76.72. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, meeting the consensus estimate of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The business had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same period in the previous year, the firm posted $0.64 EPS. The firm’s revenue was up 13.3% compared to the same quarter last year. As a group, equities analysts expect that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.